Hansen A, Vestergaard P, Poulsen M, Rasmussen A, Feldt-Rasmussen U, Madsen M
Cancers (Basel). 2025; 17(3).
PMID: 39941743
PMC: 11816337.
DOI: 10.3390/cancers17030374.
Ponder B, Kurzawinski T, Kurzawinski T
Endocr Relat Cancer. 2025; 32(4).
PMID: 39913251
PMC: 11896642.
DOI: 10.1530/ERC-24-0226.
Carra S, Gaudenzi G, Franceschetti G, Collini M, Sironi L, Bouzin M
Int J Mol Sci. 2025; 25(24.
PMID: 39769158
PMC: 11678154.
DOI: 10.3390/ijms252413392.
Clifton-Bligh R
Endocr Relat Cancer. 2024; 32(2).
PMID: 39655713
PMC: 11798414.
DOI: 10.1530/ERC-24-0224.
Kratz C
Nat Rev Cancer. 2024; 25(2):109-128.
PMID: 39627375
DOI: 10.1038/s41568-024-00775-7.
Germline alteration analysis reveals EPHB4R91H mutation as a key player in multiple primary lung tumors.
Li J, Li Y, Wang X, Zhou Z, Li X, Yue S
Carcinogenesis. 2024; 46(1).
PMID: 39574310
PMC: 11886828.
DOI: 10.1093/carcin/bgae074.
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y, Zheng W, Zhou S, Gu J, Yu Q, Zhu Y
Cell Commun Signal. 2024; 22(1):460.
PMID: 39342195
PMC: 11439284.
DOI: 10.1186/s12964-024-01837-x.
Therapeutic advances of targeting receptor tyrosine kinases in cancer.
Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A
Signal Transduct Target Ther. 2024; 9(1):201.
PMID: 39138146
PMC: 11323831.
DOI: 10.1038/s41392-024-01899-w.
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.
Toth L, Mokanszki A, Mehes G
Pathol Oncol Res. 2024; 30:1611733.
PMID: 38953007
PMC: 11215025.
DOI: 10.3389/pore.2024.1611733.
Well-defined survival outcome disparity across age cutoffs at 45 and 60 for medullary thyroid carcinoma: a long-term retrospective cohort study of 3601 patients.
Zhang K, Wang X, Wei T, Li Z, Zhu J, Chen Y
Front Endocrinol (Lausanne). 2024; 15:1393904.
PMID: 38948527
PMC: 11211583.
DOI: 10.3389/fendo.2024.1393904.
Medullary Thyroid Cancer: Epidemiology and Characteristics According to Data From the Marne-Ardennes Register 1975-2018.
Caille S, Debreuve-Theresette A, Vitellius G, Deguelte S, La Manna L, Zalzali M
J Endocr Soc. 2024; 8(6):bvae084.
PMID: 38745826
PMC: 11091837.
DOI: 10.1210/jendso/bvae084.
Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer.
Zhang W, Lin S, Wang Z, Zhang W, Xing M
J Clin Endocrinol Metab. 2024; 109(12):3166-3175.
PMID: 38735658
PMC: 11570377.
DOI: 10.1210/clinem/dgae327.
Targeted therapeutic options in early and metastatic NSCLC-overview.
Galffy G, Morocz E, Korompay R, Hecz R, Bujdoso R, Puskas R
Pathol Oncol Res. 2024; 30:1611715.
PMID: 38605928
PMC: 11006988.
DOI: 10.3389/pore.2024.1611715.
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A, Perol M, Banna G, Parikh K, Addeo A
Biomark Res. 2024; 12(1):24.
PMID: 38347643
PMC: 10863183.
DOI: 10.1186/s40364-024-00566-0.
Does Genotype-Specific Phenotype in Patients with Multiple Endocrine Neoplasia Type 2 Occur as Current Guidelines Predict?.
Binter T, Baumgartner-Parzer S, Schernthaner-Reiter M, Arikan M, Hargitai L, Niederle M
Cancers (Basel). 2024; 16(3).
PMID: 38339246
PMC: 10854710.
DOI: 10.3390/cancers16030494.
Left anterior descending artery disease in a 27-year-old with multiple endocrine neoplasia, type 2A: A case report.
Al Salihi M, Iyyani M, Koilpillai S, Quintero G, Parellada J, Carlan S
SAGE Open Med Case Rep. 2023; 11:2050313X231212095.
PMID: 38022857
PMC: 10655645.
DOI: 10.1177/2050313X231212095.
MEN 2B CASES WITH ATYPICAL PRESENTATION, UNUSUAL CLINICAL COURSE AND A LITERATURE REVIEW.
Keskin C, Canpolat A, Canlar S, Bahcecioglu Mutlu A, Erdogan M
Acta Endocrinol (Buchar). 2023; 19(2):260-266.
PMID: 37908885
PMC: 10614576.
DOI: 10.4183/aeb.2023.260.
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the .
Sahakian N, Castinetti F, Romanet P
Cancers (Basel). 2023; 15(19).
PMID: 37835559
PMC: 10572078.
DOI: 10.3390/cancers15194865.
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X, Xu C, Wang Q, Wang W, Wu F, Cai X
Thorac Cancer. 2023; 14(31):3166-3177.
PMID: 37718634
PMC: 10626248.
DOI: 10.1111/1759-7714.15105.
Progress in Thyroid Cancer Genomics: A 40-Year Journey.
Fagin J, Nikiforov Y
Thyroid. 2023; 33(11):1271-1286.
PMID: 37668657
PMC: 10664575.
DOI: 10.1089/thy.2023.0045.